3 March 2023
Latham & Watkins Advises on Travere Therapeutics’ Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Cheston Larson Lead | Latham & Watkins LLP | Partner | capital markets | San Diego |
| Matt Bush Lead | Latham & Watkins LLP | Partner | capital markets | San Diego |
| Anthony Gostanian | Latham & Watkins LLP | Counsel | capital markets | San Diego |
| Sterling Swift | Latham & Watkins LLP | Associate | capital markets | San Diego |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 200m (US$200.0 million)
- What the figure measures
- Issue size
- Client
- Latham & Watkins LLPUnderwriters
- Counterparties
- Travere Therapeutics, Inc. (Issuer)